Welcome to our dedicated page for DBV Technologies S.A. news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on DBV Technologies S.A. stock.
DBV Technologies S.A. (symbol: DBVT) is a clinical-stage specialty biopharmaceutical company revolutionizing the treatment of food allergies, a significant and growing public health issue. Founded in 2002, the company has developed a groundbreaking technology platform known as Viaskin®.
Viaskin® employs epicutaneous immunotherapy (EPIT), a proprietary method that administers allergens through an epicutaneous patch applied to intact skin. This innovative approach targets Langerhans cells, specialized immune cells in the skin, which capture the allergen and migrate to the lymph nodes. This mechanism allows for activation of the immune system without introducing the allergen into the bloodstream, thus minimizing systemic exposure and the risk of severe allergic reactions.
DBV Technologies' flagship product, Viaskin Peanut, is designed for peanut-allergic patients. The patch aims to improve patient tolerability to peanuts and significantly reduce the risk of life-threatening allergic reactions upon accidental exposure. Clinical trials have demonstrated the product's efficacy and safety, making it a promising solution for millions of individuals affected by peanut allergies.
In addition to peanut allergies, DBV Technologies is expanding its portfolio to address other food allergies like milk. The company's robust pipeline and innovative approach position it at the forefront of allergy treatment research.
DBV Technologies has secured multiple worldwide patents for its Viaskin® technology, underlining its pioneering role in the field of immunotherapy. The company continually collaborates with leading research institutions and partners to advance its clinical programs and bring new therapies to market.
Recent achievements include significant milestones in clinical trials, regulatory submissions, and strategic partnerships, reflecting DBV Technologies' commitment to developing safe and effective treatments for food allergies. The company's dedication to addressing unmet medical needs ensures it remains a crucial player in the biopharmaceutical landscape.
As of January 31, 2021, the company reported a total of 54,929,187 shares outstanding. This includes 54,883,187 net voting rights, calculated by subtracting shares without voting rights from the total shares. This report adheres to Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies released its Half-Year Report on the liquidity contract with ODDO BHF, detailing its assets as of December 31, 2020. The liquidity account held 112,302 shares and €229,086.53, compared to 24,313 shares and €682,454.94 at contract signing in July 2018. During the second half of 2020, 1,180 purchases and 1,136 sales were executed, totaling 517,291 shares bought for €2,005,858.40 and 458,090 shares sold for €1,841,496.60.
DBV Technologies (Ticker: DBVT) announced on January 14, 2020, that it received feedback from the FDA concerning its Viaskin™ Peanut patch for treating peanut allergies in children aged 4-11. Following a Complete Response Letter, the FDA provided guidance on patch modifications and the need for a new human factors study. DBV aims to start prototype selection in Q1 2021 and plans to submit a safety trial protocol in Q2 2021. The company is optimistic about extending its cash runway to the second half of 2022 due to ongoing restructuring efforts.
DBV Technologies has transitioned to a U.S. domestic issuer, effective January 1, 2021, requiring compliance with SEC regulations. The company will file periodic reports in U.S. dollars and continue with IFRS reporting in Europe. A global restructuring process, approved today, will cut over 200 jobs, leaving a team of 90, expected to enhance operational efficiency for the Viaskin Peanut development. DBV anticipates a 40-50% reduction in monthly cash burn by mid-2021, aiming to extend its cash runway into the second half of 2022.
Monthly Update: As of December 31, 2020, the company reported a total of 54,929,187 shares and 54,929,187 voting rights on the NYSE Euronext Paris. The net voting rights total was 54,816,885, accounting for shares without voting rights.
This disclosure adheres to Article 223-16 of the General Regulations of the Autorité des Marchés Financiers, ensuring transparency and compliance in reporting shareholding details.
As of November 30, 2020, the company reported a total of 54,929,187 shares outstanding on the NYSE Euronext Paris. The total number of voting rights associated with these shares is 54,929,187, while the net total of voting rights, accounting for shares without voting rights, stands at 54,815,187. This information complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies announced leadership changes with Dr. Hugh Sampson stepping down as Chief Scientific Officer effective December 1, 2020. He will transition to a role as Scientific Adviser to the CEO, remaining involved with the development of the epicutaneous immunotherapy platform. Dr. Sampson, who has been influential in advancing food allergy treatments, believes this change allows him to refocus on his research at Mount Sinai. DBV’s commitment to the Viaskin technology remains strong as they continue clinical trials aimed at food allergies.
Company Update: As of October 31, 2020, the total number of shares for the Company is 54,927,187, with a total number of voting rights amounting to 54,927,187 (gross) and 54,786,929 (net). This data reflects compliance with the Autorité des Marchés Financiers regulations.
Market: NYSE Euronext Paris | ISIN Code: FR 0010417345
DBV Technologies will present new data on its Viaskin™ Peanut treatment at the ACAAI Annual Scientific Meeting from Nov. 13-15, 2020. Key highlights include four accepted abstracts, with one oral presentation and three poster presentations, detailing the treatment's patient experience, patch adhesion, and prediction of desensitization to peanuts. The event will also feature a symposium on managing food allergies during the COVID-19 pandemic. DBV's ongoing commitment to innovative treatments aims to ease the burden of peanut allergies for patients and families.
DBV Technologies announced its participation in several upcoming virtual investor conferences. CEO Daniel Tassé will host fireside chats at the following:
- Credit Suisse Healthcare Conference: November 11, 2020, at 12:30 PM ET
- Stifel Healthcare Conference: November 16, 2020, at 8:00 AM ET
- Evercore HealthconX: December 1, 2020, at 12:35 PM ET
Webcasts will be available on the company’s website, with replays posted afterward. DBV focuses on developing Viaskin™, an innovative immunotherapy platform for food allergies.
FAQ
What is the current stock price of DBV Technologies S.A. (DBVT)?
What is the market cap of DBV Technologies S.A. (DBVT)?
What does DBV Technologies S.A. specialize in?
What is Viaskin® technology?
What is Viaskin Peanut?
How does Viaskin® technology minimize the risk of allergic reactions?
What other food allergies is DBV Technologies targeting?
When was DBV Technologies founded?
What are some recent achievements of DBV Technologies?
What is the significance of DBV Technologies' patents?
How does DBV Technologies collaborate with other institutions?
What is the financial condition of DBV Technologies?
